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Dextransucrases are a type of Glucosyltransferase (Gtf) which have many industrial 
applications, including oral care and baking, and have been identified as a biologically 
relevant target to inhibit. There are many advantages to designing a small protein affibody 
to accomplish this goal compared to using antibodies and small molecule inhibitors, 
including their inherent stability, expressibility, and engineerability. Affibodies are small 
protein domains, the original IgG binding surface of which can be varied combinatorially 
to produce tight binders to diverse protein targets. Yeast display provides a powerful tool 
to assemble and rapidly screen large libraries for binders against the target of interest, Gtfs. 
Initial studies showed the wild-type affibody could be successfully expressed and exhibit 
binding to an IgG antibody in the yeast display system. Following this, a valid approach to 
designing, assembling, and expressing an affibody variant library in this yeast display 
system was systematically employed. The assembled library contained an estimated 2.5 x 
108 members, and a sampling of this library illustrated the high quality and diversity of 
these variants. Initial surface display analysis indicated sufficient library expression level, 
as well as an anticipated disruption to IgG binding.  
The affibody variant library was enriched and sorted for Gtf binders using 
fluorescent activated cell sorting under several different conditions. Upon analysis of the 
binding populations, a potential Gtf binding motif was uncovered. Moreover, a dominant 
variant identified was found to be present in the majority of the libraries analyzed, 
regardless of sorting conditions. This highly represented variant was confirmed as a 
specific Gtf binder, with a dissociation constant in the range of tens to hundreds nanomolar. 




for Gtf inhibition. Though no Gtf inhibitors were found in these select few variants 
analyzed, the results from this screening demonstrate great promise to obtain such a 
molecule. Furthermore, the findings from this library screening could be strategically 
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 Glucosyltransferases (Gtfs) are a well-known class of enzymes which have the 
ability to transfer a sugar residue from a donor to an acceptor molecule, forming glycosidic 
linkages. Bacterial Gtfs are vital to the biosynthesis of peptidoglycan, which provides cell 
wall rigidity (1, 2). Gtf members of the glycoside hydrolase family 70, known as 
dextransucrases, primarily create soluble alpha 1,6-linked polymers from sucrose (Figure 
1). Dextransucrases are specifically found in seven species of the lactic acid bacteria 
genera: Leuconostoc, Lactobacillus, Streptococcus, and Weissella (3). Weissella confusa 
and Weissella cibaria dextransucrases are distinct enzymes with application in sourdough 
fermentation. The addition of these dextran-producing strains can improve the texture and 
quality of bread (3, 4).  
 Gtfs, including dextransucrases, from Leuconostoc and Streptococcus have been 
implicated as a driving force behind the formation of plaque (biofilms) (5); through the 
secretion of these enzymes, sucrose is polymerized into an extracellular structural matrix 
to allow the formation of a biofilm of entire communities of oral bacteria on enamel (1, 6). 
Secreted dextransucrases can adsorb to the tooth surface and produce soluble material, 
which can be used as a primer for primer-dependent Gtfs to generate insoluble 
polysaccharides (primarily alpha 1,3-glucosyl linkages), which is necessary to provide sites 
for matrix formation (1, 2).  Approximately a fifth of the dry weight of plaque is composed 




 Due to their diverse functionality and uses, Gtfs have been recognized as an 
industrial relevant target in a variety of applications. Identification of inhibitors to these 
enzymes could be beneficial in novel ways. For instance, a Gtf inhibitor could serve as an 
antimicrobial molecule with potential to be used in the oral hygiene market (8). 
Additionally, an inhibitor could provide a way to adjust the structure of dextran being 
generated (7) which could provide advantageous new qualities in the food industry.  
 
Glucosyltransferase Inhibitors 
Targeted inhibition of Streptococcal Gtf enzymes may provide an effective 
antimicrobial approach; however, this is a challenging endeavor because the donor and 
acceptor molecule binding affinities are unusually low (9). Additionally, small inhibitor 
molecules may result in acquired bacterial resistance, which is difficult to combat with 
small molecules (10). There are several Gtf-specific antibodies available today. However, 
the binding of a Gtf antibody does not necessarily inhibit activity, and of those which truly 
inhibit activity, there are very few which show efficacy in vivo (11). It is also important to 
note that antibody discovery and production are typically expensive ventures. Plaque 
presentation requires continuous dosing, making low production costs of an inhibitor a 
desirable objective. Additionally, the large molecular size of antibody inhibitors may limit 
diffusive penetration to certain niches. 
Numerous Gtf inhibitors to both crude Gtf extracts and specific Streptococcal 
enzymes have been previously found, including over thirty inhibitors which were derived 
from natural products, synthesized inhibitors, antibodies, metal ions and oxidizing agents. 




antibody have had evidence of cariostatic efficacy in vivo. The major challenge 
acknowledged in this pursuit is the ability to inhibit the Gtf enzymes which have adhered 
to the surface of the enamel or are attached to the surface of the bacterial cell. Furthermore, 
none of these molecules have yet been cleared for therapeutic use. (11-13) The difficulty 
of identifying Gtf inhibitors is attributed to their complicated reaction mechanisms, as well 
as their unusual conformational plasticity (14). Inhibitors do not necessarily need to 
sterically block the active site of the enzyme, but can also interfere with the catalytic 
mechanism of the enzymes (14, 15). Presumably, disruption of the folding or supra-
molecular structure of Gtfs may also result in effective inhibition. 
 Interestingly, it has been found that some Gtf antibodies can influence not only the 
amount of Gtf polysaccharide production, but also the shape of the material. This concept 
was found to be particularly relevant for Streptococcal Gtfs, as primer-dependent Gtfs 
could have a decreased ability to bind to Gtf-priming material generated in the presence of 
the Gtf antibody. The shape of the enamel matrix formation can be affected, ultimately 
altering the formation of biofilms. Additionally, the presence of Gtf antibodies was found 
to modify the actual sugar linkages themselves; Gtfs which formed primarily insoluble 
alpha 1,3-linkages produced an increased amount of soluble alpha 1,6-linkages in the 
presence of a Gtf antibody. The ability to change the quantity, linkage, and solubility of 
the material could be beneficial in industrial applications while also providing new 








 A small, economically produced protein scaffold could not only provide a way to 
inhibit Gtf enzymes, but also offer a plasticity to predict and address future bacterial 
resistance. Affibodies are significantly smaller than antibodies, and will also have the 
advantage of stability and ease of production. This 58-amino acid protein was derived from 
a staphylococcal cell wall protein. There are no disulfide bonds in affibodies, which contain 
three alpha helices (Figure 2) that can be reversibly folded. Affibodies have been used as 
engineerable scaffolds for many different biotechnological, diagnostic, and therapeutic 
applications (16). Thirteen solvent-exposed residues on helix one and two, originally an 
IgG-binding domain, can be randomized to acquire new binding properties (16, 17). The 
small size, high binding specificity, lack of cross-reactivity, high binding affinity, and 
overall stability properties make affibodies optimal proteins to engineer for new binding 
activities (18). 
 Affibodies have been successfully targeted to a wide variety of proteins. For 
instance, affibodies have been designed as enhanced picomolar affinity binders to 
epidermal growth factor receptor 2, a cancer specific cell surface receptor (16). Many other 
tumor-targeting antigens have been targeted successfully by affibody libraries, including 
EGFR, IGF1R, and HER3 in the low nanomolar affinity range. Affibodies have also been 
designed as biosensors, imaging molecules, and capture agents. (17-19)  
 
Yeast Display 
 Protein display systems are powerful protein engineering tools used for rapid in 




express library variants on the surface of the cells. Fluorescence activated flow cytometry 
(FACS) is used in conjunction with display systems to successfully isolate binders with 
high affinity to new targets. Saccharomyces cerevisiae has been identified as a particularly 
advantageous surface display host in which to assemble large numbers of well-folded and 
highly-expressed variants (20).  
 Using an inherent ability called gap repair, recombinant DNA can be rapidly 
assembled within yeast cells. This process allows linearized DNA fragments, typically 
containing a digested replication vector and the systematically randomized sequence of the 
variant, to be transformed into the yeast where they are assembled into circular DNA by 
the cell DNA repair machinery.  In addition to this effective transformation method, the 
yeast cells also contain a strict protein quality control system, minimizing the generation 
of misfolded or otherwise incorrect protein variants. (20) 
 To achieve yeast surface expression of the protein scaffold of interest, the affibody 
variant is fused to the C-terminus of the yeast protein Aga2 (Figure 3A).  The addition of 
a C-terminal epitope tag allows expression and binding to be monitored independently. 
Aga2 is a mating protein which covalently binds to Aga1, a GPI-anchored membrane-
associated protein on the yeast surface. In this yeast display system, these mating proteins 
are regulated by a galactose inducible promoter. When using this system to express 
variants, this inducibility allows for the decoupling of the expression of the engineerable 
protein and the cellular division. This is desirable for variants which may be toxic to the 
cell, and is a property which provides a benefit over other display systems (i.e. phage 
display). The final induced yeast cell displays a variant anchored on the cell surface and 




Since the plasmid system used to harbor the Aga2-fused variant has a centromeric origin 
of replication, the copy number maintained in the cell is essentially one, allowing for 
efficient, 1:1 coupling of the genotype and phenotype. (20, 21) 
 Using an affibody protein as a scaffold backbone, large libraries of variants can be 
displayed on the surface of yeast and screened for target binding using fluorescence 
activated cell sorting (FACS). Flow cytometric sorting of S. cerevisiae surface display 
libraries is a well-established technique to separate desired cells from a complex mixture 
(Figure 4). Yeast cells expressing library variants on their surface can be incubated with a 
fluorescently-labeled target molecule which can bind to specific variants. This renders only 
the cells containing variants with target binding properties fluorescent. An additional 
antibody with affinity for the C-terminal epitope tag and a different fluorescent emission 
wavelength, can be used to detect the overall expression of the affibody. A flow cytometer 
can detect and sort the cells which emit a signal from those without fluorescence. 
 With this method, yeast cells with highly expressed variants, as well as target 
binding activity, can be selected. The separated cells can be recovered and sequenced to 
identify the variant with binding activity. Millions of individual cells can be analyzed and 
sorted in a relatively short amount of time, providing an exceptional platform to screen 
large libraries of variants within a single mixture (20). Often, a weak binder to a target is 
obtained from a large and diverse library after only a few rounds of sorting. Further 
mutagenesis can result in designing a tight binder to the target, which can then be tested 




III. Materials and Methods 
 
Gtf Purification 
 Previously generated E. coli ultrafiltrate of recombinant Dextransucrase from W. 
confusa (AHU88292) was obtained from DuPont Industrial Biosciences (Dr. Rong Guan). 
Sample was diluted in half with 2x binding buffer (40mM Sodium Acetate, pH 5.5). 2% 
bed volume (v/v) of a 50% slurry of preequilibrated Sephadex75 resin was added to sample 
and rocked for 30 mins at room temperature. The resin was applied to a 10ml benchtop 
column and washed with 10x column volumes (CV) of binding buffer. Protein was eluted 
with 1% dextran (MW 10000). Sample was concentrated using PES 3kD MWCO filtration 
and quantitated using A280.  
 
Gtf Labeling 
 Purified protein was buffer exchanged to PBS, pH 8.0 using a PES 3kD MWCO 
spin column. Biotinylation of purified Gtf was performed using the Solulink ChromaLink 
Biotin Protein Labeling Kit. Biotinylation was performed three separate times. Final molar 
ratio of Biotin:Gtf was 7.5, 15, 12 for runs 1, 2, and 3, respectively.  FITC labeling of 
purified Gtf was performed using the Pierce™ FITC Antibody Labeling Kit. Final molar 
ratio of FITC:Gtf was 2.5.  
 
Gtf Activity Assessment 
Polymerization reactions were carried out in 20mM sodium acetate pH 5.5, 1% 




at 40C for 18 hours. For quick analysis, sample was checked visually for high viscosity, 
manifested in a gel-like form. For more thorough analysis, activity was monitored using 
HPLC, measuring sucrose consumption over time.   
 
Affibody Library Design 
 The Z-domain of staphylococcal protein A (pdb: 2SPZ) was used as a backbone for 
mutagenesis. Thirteen amino acids were targeted for an oligonucleotide-directed 
mutagenesis library (22), highlighted in cyan below: 
 
1                       10                     20                       30                    40                       50                    
VDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLND 
           58 
AQAPK 
 
 Codons were optimized for Saccharomyces cerevisiae using Integrated DNA 
Technologies Codon Optimization Tool. A Trimer Oligonucleotide Library was ordered 
from the Yale Keck Oligonucleotide Synthesis facility. These libraries use a mix of 19 
codon trimer phosphoramidites to randomize selected amino acid positions, yielding a 
more uniform distribution of amino acids across the variable region than single base 
randomization schemes, and allowing for the exclusion of undesirable variation (here, 
cysteines and stop codons) that reduce library performance. The following synthesized 






GGT GGA GTT GAT AAC AAG TTC AAC AAG GAA xxx xxx xxx GCG xxx xxx GAA 
ATT xxx xxx TTG CCC AAT TTG AAC xxx xxx CAG xxx xxx GCC TTC ATC xxx 
TCA CTG xxx GAC GAT CCA TCT CAA TCC GCG AAT 
 














Affibody Library Extension and Amplification 
 The single stranded oligonucleotides were first annealed by combining 10uM 
synthesized trimer library oligonucleotides with 10uM AfflibR’ and 1X NEB buffer 2. 




annealed oligonucleotides were then extended to double stranded DNA using the NEB 
DNA Polymerase I, Large (Klenow) Fragment in multiple 63ul reactions at 2.5U/reaction, 
2.4uM annealed oligonucleotides, 1X NEB buffer 2, and 159uM dNTPs. Reaction was 
incubated at room temperature for 1 hour. Extension success and fragment concentration 
estimation were executed by ethidium agarose gel. The extended library was amplified 
using PCR and PFU ultra II polymerase.  
 
Affibody Library Transfection into Saccharomyces cerevisiae  
 Large scale transfection was performed according to the Gietz High-efficiency 
yeast transformation using the LiAc/SS carrier DNA/PEG method (23). Diversity was 
estimated by performing a series of dilutions of the transfected material in triplicate, plating 
on 100 x 15 mm petri dishes with SD-Trp Agar. The number of colonies on the 
10/1,000,000 and 1/1,000,000 dilution plates were counted. After transfection, several 
passages of cells encompassing 10X library diversity was performed, assuming 1 OD600 = 
18.5 million cells. A freezer stock encompassing 10X library members was made and 
stored at -80C. 
 
Quality Control of Affibody Library 
 After three passages of the transfected culture, 6ml was prepped using a Zymoprep 
Yeast Miniprep Kit. The extracted DNA was transformed into NEB® 5-alpha Competent 
E. coli (High Efficiency) cells. 95 colonies were selected for ampicillin resistance and their 




Kit. Invotrogen’s commercially available CYC1 transcription termination signal reverse 
primer was used to sequence affibody sequence. 
 
Naïve Library Induction and Analysis 
 Yeast induction was performed using the Wittrup lab protocol (24). After induction, 
1 million cell aliquots were collected and washed extensively with 1x PBS with 0.5% BSA. 
An aliquot was incubated with unlabeled NFKappaB p65 rabbit antibody at 1:50 dilution 
for 1 hour at room temperature. Cells were then collected and washed extensively, and then 
incubated with 1:50 dilution of anti-rabbit IgG Alexa 647 antibody for 15 minutes. Cells 
were collected and washed extensively. A 1:100 dilution of HA rabbit 488 antibody was 
added to cells. One aliquot was kept as an unstained control, while another was only stained 




 Enrichment of the affibody library for Gtf binders was performed by overnight 
incubation of 10X library diversity with 100nM biotin-labeled Gtf at 4C on an inverter.  
Separation of Gtf bound cells was performed using Miltenyl Biotech MACS separation 
protocol. Briefly, incubated cells were washed extensively to remove free biotin-labeled 
Gtf. Streptavidin coated microbeads were added to the washed cells. Cell suspension was 
loaded onto an equilibrated MACS LS column placed in a MACS Separator magnetic field. 
The captured cells were washed extensively, then removed from the magnetic field to elute. 





FACS Sort1-Sort 3 
 The induced naïve affibody library and bead enriched library were incubated with 
50nM FITC-labeled Gtf and Alexa 647 conjugated HA-Tag antibody for 2 hours on an 
inverter at RT. The resultant samples were sorted using FACS, selecting for high signal in 
both channels. Samples were regrown, re-induced, and analyzed for binding using a 
titration of Gtf concentrations. For this analysis, various titrations of Gtf were incubated 
with 20 million cell aliquots overnight at 4C on an inverter. An additional target, TNF-
alpha was also included.  Libraries were subsequently taken forward two additional FACS 
sorts using the described regrowth, induction, and overnight Gtf incubation method, with 
a target concentration of 6nM FITC-labeled Gtf. 
 
Library DNA Extraction and Analysis 
 Library DNA was prepped using a Zymoprep Yeast Miniprep Kit. The extracted 
DNA was transformed into NEB® 5-alpha ElectroCompetent E. coli (High Efficiency) 
cells under ampicillin selection. DNA from 96 colonies was prepared for Sanger 
sequencing using an Illustra TempliPhi DNA Amplification Kit. Invotrogen’s 
commercially available CYC1 transcription termination signal reverse primer was used to 
sequence affibody sequence. Sequence analysis was performed using Geneious 







Affibody Variant Expression  
 Identified candidate sequences were codon optimized for E. coli using Integrated 
DNA Technologies Codon Optimization Tool and ordered as synthetic gene blocks. Each 
sequence was designed to have 25 base pairs of homology to the pET28a replicating 
plasmid including an N-terminal His-Tag. Each variant was assembled using NEBuilder® 
HiFi DNA Assembly Cloning Kit and transformed into NEB® 5-alpha Competent E. coli 
(High Efficiency) cells. DNA was prepared for Sanger sequencing using an Illustra 
TempliPhi DNA Amplification Kit. Sequence verified plasmids were transformed and 
expressed in One Shot™ BL21(DE3) Star Chemically Competent E. coli. Variants were 
purified using nickel affinity chromatography and analyzed using SDS-PAGE. Extinction 
coefficients were calculated using Expasy (28) and concentration was estimated using A280. 
 
Affibody Binding Validation 
 Purified Variant A was analyzed using an Octet HTX System from ForteBio. Using 
Anti-Penta-HIS Biosensors, Variant A was captured and immobilized. The binding curves 
were assessed using two-fold serial dilutions of purified Gtf. All analysis was performed 
in PBS with 0.5% BSA. The Octet software was used for binding analysis and dissociation 
estimation. Raw data was inverted for binding analysis fit curves. 
 
Affibody Inhibition Assessment 
Each purified affibody was pre-incubated with 100nM unlabeled Gtf for 1-2 hours 
at room temperature. Affibodies were dosed at approximately 20X the Gtf molar 




5.5. Polymerization reactions were carried out in 20mM sodium acetate pH 5.5, 100g/L 
sucrose. Samples were incubated with agitation at 30C for 18 hours. For quick analysis, 






IV. Results and Discussion 
Library Design, Assembly, and Fitness Assessment 
  To assess the feasibility of using the yeast display system for the expression of an 
affibody library, the Z-domain of staphylococcal protein A wild-type (Wt) affibody was 
first expressed using this technology and evaluated by flow cytometry (Figure 5). The Wt 
expression levels on the surface of the yeast after induction was quite high (approximately 
75% of library), approaching the practical limits of this system (20). Furthermore, this 
protein appears to be properly folded in this system, as illustrated by the ability to detect 
binding to IgG antibodies.  
 After the successful expression of Wt affibody, an affibody variant yeast display 
library was constructed. Thirteen amino acids on two of the three alpha helices were 
selected for saturation mutagenesis (Figure 6A). The creation of this library was 
strategized to anneal, extend, and amplify synthetic single-stranded DNA containing 
randomized regions, and utilize inherent gap repair within the S. cerevisiae host to 
assemble the amplified region into a yeast display vector (Figure 6B).  In each step, the 
annealed, Klenow, and PCR product were detected at the appropriate size by ethidium 
bromide stained agarose gel (Figure 6C). After large scale transfection (Figure 7A), the 
estimated diversity of the library members was 2.5 x 108.  
 Assessing the fitness of the library is critical to ensure proper diversity and confirm 
a lack of bias, maximizing the potential of acquiring variants with new binding affinities. 
For this analysis, DNA was extracted from a pool of the transfected material and 




the 13 varied positions were evaluated (Figure 7b). Nearly 80% of the library sampling 
contained proper in-frame sequences, with mutations located only at the intended positions. 
From these samples, the percent representation of each of the 20 naturally occurring amino 
acids inspected and compared to the expected representation. No obvious bias was 
observed for any amino acid residue. The lack of cysteine residues was to be expected, as 
the library mutation regions were synthesized without cysteine codons.  
 The initial surface expression of the assembled library was evaluated using flow 
cytometry (Figure 8). Approximately half of the library was properly expressed. As 
anticipated, a disruption to the natural binding to IgG was observed for the majority of the 
library population.  
 
Identification and Preparation of Target Gtf 
 
 Originally, Streptococcal Gtf targets were selected for recombinant expression and 
purification. However, this endeavor required complex optimization and was abandoned 
due to time constraints. A Dextransucrase from Weissella confusa was previously 
expressed recombinantly in E. coli. This protein was purified (Figure 9) and labeled with 
biotin or Fluorescein isothiocyanate (FITC).  
 
 Library Enrichment and Fluorescence Activated Cell Sorting 
 Two approaches were employed to probe the affibody variant library for binders; 
The use of an “Enriched” library, which utilized a magnetic bead enrichment step prior to 
the first FACS sort, and a “Non-Enriched” library, which consisted of a small sampling of 




library, the biotinylated Gtf was incubated with the inducted naïve library at 10X the 
estimated diversity. The cells bound to the biotinylated target were separated with 
streptavidin coated magnetic beads and regrown and induced. Approximately 5-10 million 
cells were isolated with this method. 
 The Enriched and Non-Enriched library were incubated with 50nm of FITC labeled 
Gtf and HA antibody conjugated with Alexa 647 for 2 hours. The resulting samples were 
sorted using FACS, selecting for cells with both high Alexa 647 and FITC signal. Roughly 
35 million events were sorted of the Enriched library, resulting in a selection of nearly 
10,000 cells. For the Non-Enriched library, approximately 111 million events were sorting, 
selecting around 12,000 cells. An analysis of this first sort (Figure 10) illustrates a 
successful selection of binders which exhibit both high yeast surface expression and 
affibody binding signal, compared to the Naïve library.  
 To ensure the binders selected in this first step exhibited target specificity, these 
libraries were also tested for binding against an unrelated target, TNF-alpha conjugated 
with Alexa Fluor 488 (Figure 11). The emerging population of binders in quadrant 2 vanish 
against this target, fully illustrating specificity for the Gtf target.  
 Each library, Enriched and Non-enriched, went through a total of three sorts. Sort 
2 and sort 3 utilized more stringent conditions, including a lower target concentration and 
a selection gate requiring higher binding signal. The purification of each library population 







Identification of Variant Members within Sorted Libraries 
 Six libraries were selected for sequence analysis: 
1. Non-Enriched Sort 2 (3nM Gtf) 
2. Non-Enriched Sort 2 (6nM Gtf) 
3. Enriched Sort 2 (6nM Gtf) 
4. Non-Enriched Sort 3 Gate A (6nM Gtf) 
5. Non-Enriched Sort 3 Gate B (6nM Gtf) 
6. Enriched Sort 3 (6nM Gtf) 
Sequences from 96 individual clones for each library were analyzed (Table 1). A total of 
25 sequences were found in at least two libraries, which represents 21% of the total unique 
sequences (Table 2). It was of note to identify the increase of representation of several 
sequences between sort 2 and sort 3 of each library, illustrating the path of purification 
during each round. 
  For each of the libraries after sort 3, many unique sequences emerged (Figure 13a). 
The Non-Enriched Sort 3 Gate A had three unique sequences, the dominant making up 
97% of the library, with a second sequence differing only by a single amino acid. This 
sequence was found in all of the libraries assessed, aside from one. This library, the Non-
Enriched Sort 2 (6nM Gtf) library, had lower quality sequencing reads which may account 
for not finding this sequence. 
  The Non-Enriched Sort 3 Gate B library contained 22 unique sequences (Figure 
13b), with one member occurring 23%, and an additional three each representing 11% of 
the sampling. The Enriched Library Sort 3 had twenty unique sequences (Figure 13c), with 




many stop codons, a result of insertions and deletions upstream of the variable region. Of 
the sequences identified, only seven had mutations only in the intended positions. An 
activity assessment of biotin-labeled Gtf material was performed on two separate 
biotinylated batches, and was found to be inactivated. The original material used on the 
magnetic beads was depleted, and not tested for activity; however, no attempts to 
biotinylate the Gtf yielded active protein.   
 Though there was no apparent bias seen within the quality assessment of the naïve 
library, a potential binding motif did emerge for select mutated positions in the Non-
Enriched Sort 3 Gate B population (Figure 14). Residues on the second alpha helix, 
notably mutation positions 8-12, appear to favor aromatic amino acids surrounding a 
charged residue.  
 
Binding and Inhibition Assessment of Candidate Affibody Variants 
 Sixteen of the affibody variants identified in the sort 3 libraries (Table 3) were 
cloned into E. coli and analyzed for expression. Of these sixteen, nine were expressed and 
purified successfully. The dominant sequence with the highest library representation, 
called Variant A, was analyzed for Gtf binding using several methods. A dissociation 
constant (Kd) of between 10-250 nM was estimated using an Octet HTX System biosensor 
(Figure 16). Curiously, the raw binding data obtained were manifested in an inverted 
association and disassociation curves. The negative wavelength shift is indicative of 
extremely large particles (29), such as phage and liposomes, and is an unexpected result 
considering the size of the Gtf in comparison to these large particles. It could be speculated 




the purification are binding Gtf units into aggregates that impact signal production in this 
assay method, however, more studies should be undertaken to explain this surprising 
phenomenon. Though a rough estimation, this analysis confirms Variant A as a true, non-
specific Gtf binder in the tens to hundreds of nanomolar range. This approximation agrees 
with the apparent affinities observed for the yeast-displayed variants in this population, as 
well as consistent with the selection conditions for which Variant A was isolated. This 
affibody variant could serve as an adequate backbone for further engineering to obtain an 
even tighter Gtf binder.  
 Each of the nine successfully expressed affibodies was tested for Gtf inhibition at 
several conditions. No obvious inhibition of the Gtf was observed for these expressed 
variants in end-point assays. Time-resolved inhibition assays would be more sensitive, 
particularly for the weak inhibitors expected from the first round of Gtf binding selections, 
though project time constrains did not allow for the development of this kind of kinetic 
analysis. Many factors, including the pH of the reaction and pre-incubation time length, 
may have affected the binding capacity or stability of the variant. Furthermore, a larger 
assessment of the identified sequences for both binding capacity and inhibition could be 
more foretelling of the potential to identify an inhibitor within an affibody library. It is of 
note that many of the affibody variants were not expressed successfully. However, stability 
issues may arise for these new variants expressed in solution, as compared to being stably 
tethered to the surface of a yeast cell. Additionally, many of the identified sequences had 
additional backbone mutations which may have proved fortuitous for folding, expression, 




the scope of this project, these were discounted to avoid additional complexity in validation 





V. Future Directions 
Of the numerous sequences identified as potential Gtf binders from the generated 
affibody libraries, only ten were assessed for Gtf inhibition and only one for Gtf binding. 
The remaining sequences identified from each library still maintain a high potential for 
binding and inhibiting Gtf. Improvement of expression levels, particularly of those under 
detectable levels, could be undertaken. Additionally, the binding assays used also require 
additional optimization for more precise binding measurements. Difficulties surrounding 
the potential aggregation of the Gtf in the binding assessment could be avoided by 
immobilizing the Gtf and analyzing the binding to the affibody in solution. Improved 
binding analysis could provide the validation of a Gtf-binding motif which would be 
beneficial in subsequent engineering campaigns.  
The Gtf selected for screening (a dextransucrase from W. confusa) is only one of 
many relevant Gtf targets for inhibiton. The naïve affibody variant library could be probed 
for additional binders and potential inhibitors of Gtfs from Leuconostoc and Streptococcus. 
Though a Gtf inhibitor has not yet been identified from among the isolated variants, the 
discovery of an inhibitor would warrant biophysical characterization and potential 
application screening. Improvements to the affibody inhibitor in the form of expression, 
activity, or stability could be accomplished by designing an error prone PCR library of the 
variant, as well as site saturation libraries of identified residues of interest. This type of 





Strategically, the information gained from this research could aid in the discovery 
of an inhibitor by improving the experimental design of this approach. For instance, 
screening for binders with a truncated version of an active Gtf could minimize the chances 
of isolating non-inhibitors. By minimizing the number of antigen recognition sites away 
from the active site, more relevant binding sequences could be uncovered. This is a 
stringent approach, but may increase the chances of success. Alternatively, other small 
protein binders, such as monobodies, anticalins, and designed ankyrin repeat proteins 
(DARPs) could be utilized in a similar engineering campaign in the search for a Gtf 
inhibitor (30).   
The exciting capacity of the affibody library for novel binding activities and 
potential for inhibitor discovery is not limited to Gtfs. Other biologically relevant targets 
should also be examined. Considering the ease of assembly and rapid screening 
possibilities, this approach is a powerful alternative to antibody discovery and design. As 
more information is acquired for this small protein, it is conceivable a model could be 
constructed to rationally predict variants for desired binding properties. This modeling tool 









An affibody yeast display library was successfully assembled with high fitness and 
probed for Gtf binders. Analysis of a single variant has validated the approach to locate Gtf 
binders within the range of ten to hundreds of nanomolar binders. The examination of a 
small sampling of variants within additional binding populations did not unearth an 
inhibitor; however, it is still plausible that this approach will lead to such a molecule. This 
effort yielded an abundence of valuable insight for future strategies, which can be 
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Table 1. Summary FACS Sorted Libraries Sequence Analysis 
 
 
Library Good Clones Unique Sequences seq >10 % library
NE sort 2, 3nM 80 14 2
NE sort 2, 6nM 69 26 3
E sort 2 92 34 1
NE sort 3 Gate A 93 3 1
NE sort 3 Gate B 94 22 4









A summary of the 25 shared sequences, located in two or more libraries analyzed, 
containing the libraries of origin and a heat map of library representation. 
 
 
Table 3. Sequences Selected for Expression, Binding and Inhibition Analysis 
The sixteen affibody variants which were selected for expression and inhibition studies. 
Seven of the sixteen were not expressed successfully, and the remainder did not 
demonstrate Gtf inhibition in an end-point assay. The library associated with each sequence 
is listed, with the Non-Enriched Gate A (Sort 3) library annotated as library 1, the Non-
Enriched Gate B (Sort 3) as library 2, and Enriched (Sort 3) as library 3.  Mutated residues 






Figure 1. Dextransucrase Reaction (Adapted from 31) 
Dextransucrase are glucosyltransferases (Gtfs) which catalyze the transfer of a sugar 





Figure 2. Z-domain of Staphylococcal Protein A (pdb 2spz) (32) 
The affibody wild-type (Wt) backbone commonly used for protein engineering new 
binders. Comprised of just three connected alpha helices, this small protein exhibits 




mutations on thirteen identified residue positions on two of the three alpha helices offers 






Figure 3. Construction of a Yeast Display Affibody Library  
Illustration representing the A) Surface expression construct B) The affibody Aga2 fusion 
protein surface expression system (Illustration adapted from 20). The assembled construct 
contains a galactose inducible system used to initiate expression and localization of 
affibody variant to the extracellular surface of the yeast by covalent binding of the 
reproductive proteins Aga1 and Aga2. The affibody additionally contains an HA epitope 
for expression assessment. Anchored to the surface of yeast, the affibody can bind to 







Figure 4. FACS Sorting Yeast Display Libraries 
A simplified illustration of FACs analysis used to sort a library of variants. Each dot 
represents a single cell event. Variants are displayed on the surface of the yeast with a 
fluorescent tag to detect expression levels. To be sorted out of the sample solution, the 
yeast cell must have a high expression level in addition to a signal from the bound 





Figure 5. Analyzing Wt Yeast Display Library 
Flow cytometry density plots illustrating Wt affibody expression (x-axis) and IgG binding 
(y-axis) within the yeast display system. No background in either fluorescence channel was 
detected for unstained cells. The Wt library exhibited high expression levels in the yeast 
display system. Nearly all of the expressed population were shown to have bound to IgG, 






Figure 6. Design and Cloning Strategy of an Affibody Variant Library 
A) The structure of the Wt affibody (pdb 2spz) at various angles, with the thirteen amino 
acids targeted for saturation mutagenesis highlighted in red. Image generated using 
PyMOL (33). B) The cloning strategy employed to assemble the affibody variant library. 
Single stranded oligonucleotides containing variable regions were annealed and extended 
in a Klenow reaction, and the resulting material was further amplified by PCR. The final 
material was transformed with the linearized cloning vector into S. cerevisiae to be 
generated in the host by gap repair.  C) Ethidium bromide stained agarose gels illustrating 








Figure 7. Diversity and Fitness Assessment of Affibody Variant Library 
A) Dilution plate of transfected yeast, used to estimate diversity. B) Sequence quality and 
amino acid bias of a sampling of the assembled variant library. 
 
 
Figure 8. Expression and IgG Binding Evaluation of Assembled Library 






Figure 9. SDS-PAGE Analysis of Purification of Gtf from W. confusa 
Ultrafiltrate of recombinantly expressed Gtf target was purified using Sephadex75 resin 





Figure 10. Analysis of FACS Sorted Libraries 
Flow cytometry density plot of the library expression levels (x-axis) and Gtf binding (y-




libraries, Non-Enriched (Sort 1) and Enriched (Sort 1). An emerging population of binders 




Figure 11. Off Target Library Binding Assessment  
The FACS sort 1 of both the Enriched and Non-Enriched library were tested for binding 














Figure 12. Gtf Binding Analysis of Library Sorts 1-3 
Flow cytometry density plot of the library expression levels (x-axis) and Gtf binding (y-




Enriched and Enriched libraries, a dose dependent binding signal is observed. After each 
round of FACS selection, an increased population of Gtf binders is observed.  
 
 
Figure 13. Library Sequence Analysis 
A sampling of A) The Non-Enriched Gate A library B) The Non-Enriched Gate B library 
and C) The Enriched library from the last round of selection (Sort 3) were analyzed for 







Figure 14 Potential Gtf Binding Motif 
An analysis of the population of binders from the Non-Enriched Library Gate B (Sort 3) 
illustrates a potential emergence of a binding motif found on the second alpha helix, 







Figure 15 Expression Purification of Several Affibody Variants 
Sixteen sequences identified from the Sort 3 libraries were cloned, expressed, and purified 









Figure 16 Gtf Binding Curve Fit of Affibody Variant A 
The binding of Variant A was analyzed against several Gtf concentrations and the binding 
response was fit to a curve. The estimated dissociation constant was predicted to be 
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